Abstract
Psoriatic arthritis (PsA) is a chronic autoimmune disease characterized by inflammatory arthritis in association with skin psoriasis (Ps). PsA may show a heterogeneous and variable clinical course, with involvement of peripheral and axial diarthrodial joints, periarticular structures such as entheses, as well as the skin and nails. Evidence is increasing that affected patients can have significant radiographic joint damage, functional impairment, reduced quality of life (QOL) and long-term work disability. The economic burden of PsA can be considerable.
There is an increasing interest in pharmacoeconomic evaluations in PsA, driven mostly by the introduction of highly effective but expensive biologic agents, particularly inhibitors of the proinflammatory cytokine tumour necrosis factor (TNF)-α. Treatment with TNFα inhibitors results in not only substantial improvements in signs and symptoms of arthritis, but also improvements in all distinct sites of the disease, such as axial arthritis, dactylitis, enthesitis and skin disease.
There is a dearth of published pharmacoeconomic evaluations in the field of PsA. The notable clinical efficacy of the TNFα inhibitors needs to be factored into a comprehensive assessment of their value. Further analyses are needed to optimize the use of the new biologic agents in PsA.
Similar content being viewed by others
References
Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006; 33 (7): 1417–1421
Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl. 2: iil4–ii17
Husted JA, Gladman DD, Farewell VT, et al. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997; 24 (3): 511–517
Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5795 members of the Nordic Psoriasis Associations: data from the Nordic Quality of Life study. Acta Derm Venereol 2002; 82 (2): 108–113
Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23 (2): 137–145
Daltroy LH, Larson MG, Roberts NW, et al. A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 1990; 17 (7): 946–950
Blackmore MG, Gladman DD, Husted J, et al. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995; 22 (5): 886–893
Husted JA, Gladman DD, Long JA, et al. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 1995; 13 (4): 439–443
Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30 (6): 473–483
Husted JA, Gladman DD, Cook RJ, et al. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998; 25 (11): 2146–2155
McKenna SP, Doward LC, Whalley D, et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004; 63 (2): 162–169
Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356 (9227): 385–390
Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50 (7): 2264–2272
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994: 19 (3): 210–216
Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64 (8): 1150–1157
Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006; 65 (8): 1038–1043
Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52 (10): 3279–3289
Kavanaugh A, Antoni C, Krueger GG, et al. Infliximab improves health-related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006; 65 (4): 471–477
Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52 (4): 1227–1236
van der Heijde D, Gladman DD, Kavanaugh A, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: 54 week result from IMPACT 2 [abstract]. Ann Rheum Dis 2005; 52 Suppl. 9: S281
Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005; 64 Suppl. 2: ii78–ii82
Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002: 46 (6): 850–860
Kraning K, Odland GF. Psoriasis. J Invest Dermatol 1979; 73: 402–413
Krueger GG, Bergstresser PR, Lowe NJ, et al. Psoriasis. J Am Acad Dermatol 1984; 11 (5 Pt 2): 937–947
Kobelt G, Eberhardt K, Jonsson L, et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42 (2): 347–356
Merkesdal S, Ruof J, Schoffski O, et al. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001; 44 (3): 528–534
Jonsson B, Rehnberg C, Borgquist L, et al. Locomotion status and costs in destructive rheumatoid arthritis: a comprehensive study of 82 patients from a population of 13 000. Acta Orthop Scand 1992; 63 (2): 207–212
Puolakka K, Kautiainen H, Pekurinen M, et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients’ sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis 2006; 65 (7): 899–904
Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42 (6): 1209–1218
Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006; 65 (9): 1175–1183
Kavanaugh A. Economic issues with new rheumatologic therapeutics. Curr Opin Rheumatol 2007; 19 (3): 272–276
Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005; 52 (1): 1–19
Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I: causes and risk of death. Arthritis Rheum 1997; 40 (10): 1868–1872
Gladman DD, Farewell VT, Wong K, et al. Mortality studies in psoriatic arthritis: results from a single outpatient center. II: prognostic indicators for death. Arthritis Rheum 1998; 41 (6): 1103–1110
Verstappen SM, Jacobs JW, van der Heijde DM, et al. Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. Ann Rheum Dis 2007; 66 (6): 727–731
Boonen A, van der Heijde D, Landewe R, et al. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003; 62 (8): 732–740
Boonen A. A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nat Clin Pract Rheumatol 2006; 2 (10): 546–553
Feldman SR, Fleischer Jr AB, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37 (4): 564–569
Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006; 212 (2): 137–144
Galadari I, Rigel E, Lebwohl M. The cost of psoriasis treatment. J Eur Acad Dermatol Venereol 2001; 15 (4): 290–291
Finzi AF, Mantovani LG, Belisari A. The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study: Associazione Italiana Studi Psoriasi. J Eur Acad Dermatol Venereol 2001; 15 (4): 320–324
Bansback NJ, Ara R, Barkham N, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 2006; 45 (8): 1029–1038
Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006; 10 (31): iii–iv, xiii-xvi, 1-239
Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39 (12): 2013–2020
Kavanaugh A, Antoni C, Mease P, et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 2006; 33 (11): 2254–2259
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52 (11): 3381–3390
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146 (6): 406–415
Acknowledgements
No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ackermann, C., Kavanaugh, A. Economic Burden of Psoriatic Arthritis. Pharmacoeconomics 26, 121–129 (2008). https://doi.org/10.2165/00019053-200826020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200826020-00003